CDSCO meets WHO standards for functional vaccine regulatory system

A team of international experts from various countries led by the World Health Organisation (WHO) headquarters in Geneva reviewed India's vaccine regulatory system

WHO, World Health Organization
India retains maturity level 3 with highest marks in several functions. (Photo: Shutterstock)
Press Trust of India New Delhi
2 min read Last Updated : Oct 11 2024 | 3:44 PM IST

Drug regulator CDSCO and the National Regulatory Authority of India have met the standards set up by the World Health Organisation for a functional vaccine regulatory system

A team of international experts from various countries led by the World Health Organisation (WHO) headquarters in Geneva reviewed India's vaccine regulatory system from September 16 to 20, the health ministry said in a statement.

Safety, efficacy, and quality were the three basic parameters of assessment of vaccines, it said.

The WHO has established global standards and benchmarks for assurance of vaccine quality through the development of tools and guidelines, benchmarking of the National Regulatory Authorities (NRA) and pre-qualification programme of vaccines, the statement said.

The WHO NRA re-benchmarking was aimed to assess and document the status of the India regulatory system in the area of vaccine regulation, re-benchmark the status of the India vaccine regulatory system against the WHO NRA Global Benchmarking Tool (GBT) and measuring the maturity of the system.

"India has been declared 'functional' against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI. India's vaccine regulatory system was benchmarked in 2017 against Global benchmarking tool (GBT) version V which is now revised to GBT VI with raised bars and stringency in bench-marking criteria," the statement said.

India retains maturity level 3 with highest marks in several functions.

Speaking about the achievement, Punya Salila Srivastava, Union Health Secretary, stated, "The Central Drugs Standards Control Organisation (CDSCO, in collaboration with WHO, has made exemplary efforts towards this achievement. India is one of the main players in the pharmaceutical industry worldwide and is known for its affordable vaccines and generic medicines.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Drug makers in IndiaWHOVaccine

First Published: Oct 11 2024 | 3:44 PM IST

Next Story